Hayato Yamazaki

Trial of Satralizumab in Neuromyelitis Optica Spectrum Disorder

Takashi Yamamura, Ingo Kleiter, Kazuo Fujihara et al. · New England Journal of Medicine · 2019 · 605 citations · Full text

Head-to-head comparison of the safety of tocilizumab and tumor necrosis factor inhibitors in rheumatoid arthritis patients (RA) in clinical practice: results from the registry of Japanese RA patients on biologics for long-term safety (REAL) registry

Ryoko Sakai, Soo‐Kyung Cho, Toshihiro Nanki et al. · Arthritis Research & Therapy · 2015 · 72 citations · Full text

Rheumatoid Disorder, Rheumatology, Epidemiology +11

Risk for malignancy in rheumatoid arthritis patients treated with biological disease-modifying antirheumatic drugs compared to the general population: A nationwide cohort study in Japan

Masayoshi Harigai, Toshihiro Nanki, Ryuji Koike et al. · Modern Rheumatology · 2016 · 64 citations

Drug retention rates and relevant risk factors for drug discontinuation due to adverse events in rheumatoid arthritis patients receiving anticytokine therapy with different target molecules

Ryoko Sakai, Michi Tanaka, Toshihiro Nanki et al. · Annals of the Rheumatic Diseases · 2012 · 57 citations · Full text

Optimal regimens of sulfamethoxazole-trimethoprim for chemoprophylaxis of Pneumocystis pneumonia in patients with systemic rheumatic diseases: results from a non-blinded, randomized controlled trial

Masako Utsunomiya, Hiroaki Dobashi, Toshio Odani et al. · Arthritis Research & Therapy · 2017 · 53 citations · Full text